University of California

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Research Triangle Institute

Epalex Corporation

The United States of America As Represented by the Department of Health

Shunichi Yamaguchi

Michael A. Rogawski

Mariena V. Mattson

James A. Monn

Kenneth C. Rice

Arthur E. Jacobson

Andrew Thurkauf

Michael A Rogawski

Scott P Runyon

John A Kepler

Hernan A Navarro

Matthew Orr

Rafal Kaminski

Edgar Cook

Steven L Krill

Feng-Jing Chen

Isaac N Pessah

Allen H Heller

Zhengyu Cao

Edward Brendan Magrab

Pamela J Lein

Andrew Y Thurkauf

Kenner C Rice

Arthur E Jacobson

Mariena V Mattson

James A Monn

Dorota Zolkowska

Hernan Navarro

Edgar (deceased) Cook

Kenneth C Rice

John Kepler

Cook Edgar

The present disclosure pertains to the use of fospropofol, pharmaceutically acceptable salts of fospropofol, or mixtures thereof. Pharmaceutical compositions comprising fospropofol, pharmaceutically acceptable salts of fospropofol, or mixtures thereof, and methods of treating diseases or disorders, including migraine are also disclosed.

Fospropofol methods and compositions

Provided are compositions comprising a benzodiazepine and a neurosteroid, containing one or both of the benzodiazepine and the neurosteroid in a subtherapeutic dose, and administration of such compositions for mitigation of an epileptic seizure. Further provided are compositions comprising a benzodiazepine, a neurosteroid, and an NMDA blocker, and administration of such compositions for mitigation of an epileptic seizure.

Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids

The present invention relates to the formulation of steroids, including neurosteroids (e.g., allopregnanolone (ALP)) in edible oils to enhance their absorption when administered, e.g., orally or transmucosally to a patient.

Edible oils to enhance delivery of orally administered steroids

The present invention relates to methods of preventing, inhibiting, delaying, and/or mitigating seizures by administration of a steroid, e.g., a neurosteroid, e.g., allopregnanolone.

Anticonvulsant activity of steroids

This invention describes compounds of Structures 1, 2, and 3 and their use as allosteric modulators of the GABA receptor chloride ionophore complex to alleviate stress, anxiety, mood disorders, seizures, depression, treatment of drug and alcohol abuse, memory, premenstrual disorders, and neural system damage. 

Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties

Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties

This invention describes compounds of Structures 1, 2, and 3 and their use as allosteric modulators of the GABA receptor chloride ionophore complex to alleviate stress, anxiety, mood disorders, seizures, depression, treatment of drug and alcohol abuse, memory, premenstrual disorders, and neural system damage.

This invention is in the field of clinical neurology and relates specifically to compounds, compositions and methods for treatment of patients with generalized epilepsy or partial (symptomatic) epilepsy using compounds of the formula: ##STR1## This invention also relates to compounds, compositions and methods of treatment for drug craving in patients addicted to cocaine.

5-aminocarbonyl-5H-dibenzo[a.d]cyclohepten-5,10-imines for treatment of

Growing community of inventors

Sacramento, CA, United States of America

Michael A Rogawski